Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease.
Adolescent
Adult
Aged
Cross-Over Studies
Double-Blind Method
Female
Humans
Imidazoles
/ pharmacology
Male
Middle Aged
Orexin Receptor Antagonists
/ administration & dosage
Pulmonary Disease, Chronic Obstructive
/ complications
Pyrrolidines
/ pharmacology
Respiration
/ drug effects
Sleep
/ drug effects
Young Adult
hypnotics
polysomnography
respiratory disorders
Journal
Journal of sleep research
ISSN: 1365-2869
Titre abrégé: J Sleep Res
Pays: England
ID NLM: 9214441
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
06
11
2020
received:
06
08
2020
accepted:
12
11
2020
pubmed:
9
1
2021
medline:
29
9
2021
entrez:
8
1
2021
Statut:
ppublish
Résumé
In patients with chronic obstructive pulmonary disease (COPD), sleep is often fragmented while, conversely, the use of sleep medications is of concern in these patients due to potential impairment of nocturnal breathing. This randomised, double-blind, placebo-controlled, two-period crossover study was conducted to evaluate the effect of the new dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate COPD. In each period, the highest Phase-III dose of 50 mg daridorexant or placebo was administered once daily in the evening for 5 consecutive days. The primary endpoint was peripheral oxygen saturation (SpO
Substances chimiques
Imidazoles
0
Orexin Receptor Antagonists
0
Pyrrolidines
0
daridorexant
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13248Informations de copyright
© 2020 European Sleep Research Society.
Références
Bercovitch, R. S., & Tsai, S. C. (2012). Respiratory medications and sleep. Current Respiratory Care Reports, 1, 123-130. https://doi.org/10.1007/s13665-012-0013-1
Berry, R. B., Albertario, C. L., Harding, S. M., Lloyd, R. M., Plante, D. T., Quan, S. F., Troester, M. M, & Vaughn, B. V. (2018). The AASM manual for the scoring of sleep and associated events. Rules, Terminology and Technical Specifications, Version 2.5. American Academy of Sleep Medicine.
Boof, M. L., Dingemanse, J., Lederer, K., Fietze, I., & Ufer, M. (2020). Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea. Sleep.
Brisbare-Roch, C., Dingemanse, J., Koberstein, R., Hoever, P., Aissaoui, H., Flores, S., Mueller, C., Nayler, O., van Gerven, J., de Haas, S.L., Hess, P., Qiu, C., Buchmann, S., Schertz, M., Weller, T., Fischli, W., Clozel, M., & Jenck, F. (2007). Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nature Medicine, 13(2), 150-155. https://doi.org/10.1038/nm1544
Budhiraja, R., Parthasarathy, S., Budhiraja, P., Habib, M. P., Wendel, C., & Quan, S. F. (2012). Insomnia in patients with COPD. Sleep, 35(3), 369-375. https://doi.org/10.5665/sleep.1698
Budhiraja, R., Siddiqi, T. A., & Quan, S. F. (2015). Sleep disorders in chronic obstructive pulmonary disease: Etiology, impact, and management. Journal of Clinical Sleep Medicine, 11(3), 259-270. https://doi.org/10.5664/jcsm.4540
Carrive, P., & Kuwaki, T. (2017). Orexin and central modulation of cardiovascular and respiratory function. Current Topics in Behavioral Neurosciences, 33, 157-196. https://doi.org/10.1007/7854_2016_46
Cheng, J. Y., Filippov, G., Moline, M., Zammit, G. K., Bsharat, M., & Hall, N. (2020). Respiratory safety of lemborexant in healthy adult and elderly subjects with mild obstructive sleep apnea: A randomized, double-blind, placebo-controlled, crossover study. Journal of Sleep Research, 29(4), e13021. https://doi.org/10.1111/jsr.13021
Dauvilliers, Y., Zammit, G., Fietze, I., Mayleben, D., Seboek Kinter, D., Pain, S., & Hedner, J. (2020). Daridorexant, a New Dual Orexin receptor antagonist to treat insomnia disorder. Annals of Neurology, 87(3), 347-356. https://doi.org/10.1002/ana.25680
DSM-5, (2013). American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th ed.). American Psychiatric Association.
Fietze, I., Glos, M., Zimmermann, S., & Penzel, T. (2020). Long-term variability of the apnea-hypopnea index in a patient with mild to moderate obstructive sleep apnea. Journal of Clinical Sleep Medicine, 16(2), 319-323. https://doi.org/10.5664/jcsm.8192
Fleetham, J., West, P., Mezon, B., Conway, W., Roth, T., & Kryger, M. (1982). Sleep, arousals, and oxygen desaturation in chronic obstructive pulmonary disease. The effect of oxygen therapy. American Review of Respiratory Disease, 126(3), 429-433. https://doi.org/10.1164/arrd.1982.126.3.429
Global Initiative for Obstructive Lund Disease. (2018). Global strategy for prevention, diagnosis, and management of COPD. Global Initiative for Obstructive Lund Disease report 2018. Retrieved from http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINALrevised-20-Nov_WMS.pdf
Gries, R. E., & Brooks, L. J. (1996). Normal oxyhemoglobin saturation during sleep. How low does it go? Chest, 110, 1489-1492. https://doi.org/10.1378/chest.110.6.1489
Hoyer, D., & Jacobson, L. H. (2013). Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand? Neuropeptides, 47, 477-488. https://doi.org/10.1016/j.npep.2013.10.009
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2005). E14 guideline. Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Retrieved from https://database.ich.org/sites/default/files/E14_Guideline.pdf
Jensen, L. A., Onyskiw, J. E., & Prasad, N. G. (1998). Meta-analysis of arterial oxygen saturation monitoring by pulse oximetry in adults. Heart and Lung, 27, 387-408. https://doi.org/10.1016/s0147-9563(98)90086-3
Kryger, M., Roth, T., Wang-Weigand, S., & Zhang, J. (2009). The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease. Sleep Breath, 13(1), 79-84. https://doi.org/10.1007/s11325-008-0196-4
Kryger, M., Wang-Weigand, S., Zhang, J., & Roth, T. (2008). Effect of ramelteon, a selective MT(1)/MT (2)-receptor agonist, on respiration during sleep in mild to moderate COPD. Sleep Breath, 12, 243-250. https://doi.org/10.1007/s11325-007-0156-4
Kuwaki, T. (2008). Orexinergic modulation of breathing across vigilance states. Respiratory Physiology & Neurobiology, 164, 204-212. https://doi.org/10.1016/j.resp.2008.03.011
Li, A., & Nattie, E. (2014). Orexin, cardio-respiratory function, and hypertension. Frontiers in Neuroscience, 8, 22. https://doi.org/10.3389/fnins.2014.00022
McNicholas, W. T. (2009). Chronic obstructive pulmonary disease and obstructive sleep apnea: Overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. American Journal of Respiratory and Critical Care Medicine, 180, 692-700. https://doi.org/10.1164/rccm.200903-0347PP
Merck & Co., Inc., (2018). Belsomra [package insert]. Merck & Co..
Midgren, B., Hansson, L., Ahlmann, S., & Elmqvist, D. (1990). Effects of single doses of propiomazine, a phenothiazine hypnotic, on sleep and oxygenation in patients with stable chronic obstructive pulmonary disease. Respiration, 57, 239-342. https://doi.org/10.1159/000195848
Midgren, B., Hansson, L., Skeidsvoll, H., & Elmqvist, D. (1989). The effects of nitrazepam and flunitrazepam on oxygen desaturation during sleep in patients with stable hypoxemic nonhypercapnic COPD. Chest, 95, 765-768. https://doi.org/10.1378/chest.95.4.765
Muehlan, C., Boehler, M., Brooks, S., Zuiker, R., van Gerven, J., & Dingemanse, J. (2020). Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration. Journal of Psychopharmacology, 34, 326-335. https://doi.org/10.1177/0269881119882854
Muehlan, C., Brooks, S., Zuiker, R., van Gerven, J., & Dingemanse, J. (2019). Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration. European Neuropsychopharmacology, 29, 847-857. https://doi.org/10.1016/j.euroneuro.2019.05.009
Muehlan, C., Heuberger, J., Juif, P. E., Croft, M., van Gerven, J., & Dingemanse, J. (2018). Accelerated development of the dual orexin receptor antagonist ACT-541468: Integration of a microtracer in a first-in-human study. Clinical Pharmacology and Therapeutics, 104, 1022-1029. https://doi.org/10.1002/cpt.1046
Muehlan, C., Zuiker, R., Peeters, P., Rowles, R., & Dingemanse, J. (2020). Pharmacokinetics and pharmacodynamics of the dual orexin receptor antagonist daridorexant in Japanese and Caucasian subjects. Journal of Clinical Psychopharmacology, 40, 157-166. https://doi.org/10.1097/JCP.0000000000001182
Nunes, D. M., Mota, R. M., de Pontes Neto, O. L., Pereira, E. D., de Bruin, V. M., & de Bruin, P. F. (2009). Impaired sleep reduces quality of life in chronic obstructive pulmonary disease. Lung, 187, 159-163. https://doi.org/10.1007/s00408-009-9147-5
Owens, R. L., & Malhotra, A. (2010). Sleep-disordered breathing and COPD: The overlap syndrome. Respiratory Care, 55, 1333-1344.
Roth, T. (2009). Hypnotic use for insomnia management in chronic obstructive pulmonary disease. Sleep Medicine, 10, 19-25. https://doi.org/10.1016/j.sleep.2008.06.005
Schermer, T., Leenders, J., in 't Veen, H., van den Bosch, W., Wissink, A., Smeele, I., & Chavannes, N. (2009). Pulse oximetry in family practice: Indications and clinical observations in patients with COPD. Family Practice, 26, 524-531. https://doi.org/10.1093/fampra/cmp063
Shawon, M. S., Perret, J. L., Senaratna, C. V., Lodge, C., Hamilton, G. S., & Dharmage, S. C. (2017). Current evidence on prevalence and clinical outcomes of co-morbid obstructive sleep apnea and chronic obstructive pulmonary disease: A systematic review. Sleep Medicine Reviews, 32, 58-68. https://doi.org/10.1016/j.smrv.2016.02.007
Steens, R. D., Pouliot, Z., Millar, T. W., Kryger, M. H., & George, C. F. (1993). Effects of zolpidem and triazolam on sleep and respiration in mild to moderate chronic obstructive pulmonary disease. Sleep, 16, 318-326. https://doi.org/10.1093/sleep/16.4.318
Sun, H., Palcza, J., Card, D., Gipson, A., Rosenberg, R., Kryger, M., Lines, C., Wagner, J. A., & Troyer, M. D. (2016). Effects of suvorexant, an orexin receptor antagonist, on respiration during sleep in patients with obstructive sleep apnea. Journal of Clinical Sleep Medicine, 12, 9-17. https://doi.org/10.5664/jcsm.5382
Sun, H., Palcza, J., Rosenberg, R., Kryger, M., Siringhaus, T., Rowe, J., Lines, C., Wagner, J. A., & Troyer, M. D. (2015). Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease. Respiratory Medicine, 109, 416-426. https://doi.org/10.1016/j.rmed.2014.12.010
Valipour, A., Lavie, P., Lothaller, H., Mikulic, I., & Burghuber, O. C. (2011). Sleep profile and symptoms of sleep disorders in patients with stable mild to moderate chronic obstructive pulmonary disease. Sleep Medicine, 12, 367-372. https://doi.org/10.1016/j.sleep.2010.08.017
Williams, R. H., & Burdakov, D. (2008). Hypothalamic orexins/hypocretins as regulators of breathing. Expert Reviews in Molecular Medicine, 10, e28. https://doi.org/10.1017/S1462399408000823
Zammit, G., Dauvilliers, Y., Pain, S., Sebök Kinter, D., Mansour, Y., & Kunz, D. (2020). Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Neurology, 94, e2222-e2232. https://doi.org/10.1212/WNL.0000000000009475